Burza, S., Croft, S. L. & Boelaert, M. Leishmaniasis. Lancet 392, 951–970 (2018).
Kaye, P. & Scott, P. Leishmaniasis: complexity at the host-pathogen interface. Nat. Rev. Microbiol 9, 604–615 (2011).
McGwire, B. S. & Satoskar, A. R. Leishmaniasis: clinical syndromes and treatment. QJM 107, 7–14 (2014).
Curtin, J. M. & Aronson, N. E. Leishmaniasis in the United States: emerging issues in a region of low endemicity. Microorganisms 9, https://doi.org/10.3390/microorganisms9030578 (2021).
McIlwee, B. E., Weis, S. E. & Hosler, G. A. Incidence of endemic human cutaneous leishmaniasis in the United States. JAMA Dermatol. 154, 1032–1039 (2018).
Article PubMed PubMed Central Google Scholar
Taslimi, Y., Zahedifard, F. & Rafati, S. Leishmaniasis and various immunotherapeutic approaches. Parasitology 145, 497–507 (2018).
Ghorbani, M. & Farhoudi, R. Leishmaniasis in humans: drug or vaccine therapy. Drug Des. Devel Ther. 12, 25–40 (2018).
Ponte-Sucre, A. et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl. Trop. Dis. 11, e0006052 (2017).
Article PubMed PubMed Central Google Scholar
Lainson, R. & Shaw, J. J. Leishmaniasis in Brazil: XII. Observations on cross-immunity in monkeys and man infected with Leishmania mexicana mexicana, L. m. amazonensis, L. braziliensis braziliensis, L. b. guyanensis and L. b. panamensis. J. Trop. Med. Hyg. 80, 29–35 (1977).
Porrozzi, R., Teva, A., Amaral, V. F., Santos da Costa, M. V. & Grimaldi, G. Jr. Cross-immunity experiments between different species or strains of Leishmania in rhesus macaques (Macaca mulatta). Am. J. Trop. Med Hyg. 71, 297–305 (2004).
Ostyn, B. et al. Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl. Trop. Dis. 5, e1284 (2011).
Article PubMed PubMed Central Google Scholar
Jeronimo, S. M. et al. Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up. Clin. Infect. Dis. 30, 608–609 (2000).
Nadim, A., Javadian, E., Tahvildar-Bidruni, G. & Ghorbani, M. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull. Soc. Pathol. Exot. Filiales 76, 377–383 (1983).
Kellina, O. I. Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the U.S.S.R. Bull. Soc. Pathol. Exot. Filiales 74, 306–318 (1981).
Seyed, N., Peters, N. C. & Rafati, S. Translating observations from leishmanization into non-living vaccines: the potential of dendritic cell-based vaccination strategies against leishmania. Front. Immunol. 9, 1227 (2018).
Article PubMed PubMed Central Google Scholar
Romano, A., Doria, N. A., Mendez, J., Sacks, D. L. & Peters, N. C. Cutaneous infection with Leishmania major mediates heterologous protection against visceral infection with Leishmania infantum. J. Immunol. 195, 3816–3827 (2015).
Zijlstra, E. E., el-Hassan, A. M., Ismael, A. & Ghalib, H. W. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am. J. Trop. Med Hyg. 51, 826–836 (1994).
Okwor, I. & Uzonna, J. Vaccines and vaccination strategies against human cutaneous leishmaniasis. Hum. Vaccin 5, 291–301 (2009).
Noazin, S. et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26, 6759–6767 (2008).
Scorza, B. M., Carvalho, E. M. & Wilson, M. E. Cutaneous manifestations of human and murine leishmaniasis. Int J Mol Sci. 18, https://doi.org/10.3390/ijms18061296 (2017).
Gabriel, A. et al. Cutaneous leishmaniasis: the complexity of host’s effective immune response against a polymorphic parasitic disease. J. Immunol. Res 2019, 2603730 (2019).
Article PubMed PubMed Central Google Scholar
Rosas, L. E. et al. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice. Int Immunol. 17, 1347–1357 (2005).
Paiva, M. B. et al. A cytokine network balance influences the fate of Leishmania (Viannia) braziliensis infection in a cutaneous leishmaniasis hamster model. Front Immunol. 12, 656919 (2021).
Article PubMed PubMed Central Google Scholar
Volpedo, G. et al. Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis. NPJ Vaccin. 7, 32 (2022).
Selvapandiyan, A. et al. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J. Biol. Chem. 279, 25703–25710 (2004).
Selvapandiyan, A. et al. Centrin1 is required for organelle segregation and cytokinesis in Trypanosoma brucei. Mol. Biol. Cell 18, 3290–3301 (2007).
Article PubMed PubMed Central Google Scholar
Karmakar, S. et al. Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis. Commun. Biol. 4, 929 (2021).
Article PubMed PubMed Central Google Scholar
Zhang, W. W. et al. A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nat. Commun. 11, 3461 (2020).
Article PubMed PubMed Central Google Scholar
Aslan, H. et al. A new model of progressive visceral leishmaniasis in hamsters by natural transmission via bites of vector sand flies. J. Infect. Dis. 207, 1328–1338 (2013).
Article PubMed PubMed Central Google Scholar
Dey, R. et al. Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana. J. Immunol. 193, 3513–3527 (2014).
Biedermann, T. et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2, 1054–1060 (2001).
Hurdayal, R. et al. Deletion of IL-4 receptor alpha on dendritic cells renders BALB/c mice hypersusceptible to Leishmania major infection. PLoS Pathog. 9, e1003699 (2013).
Article PubMed PubMed Central Google Scholar
Wilson, H. R., Dieckmann, B. S. & Childs, G. E. Leishmania braziliensis and Leishmania mexicana: experimental cutaneous infections in golden hamsters. Exp. Parasitol. 47, 270–283 (1979).
Melby, P. C., Chandrasekar, B., Zhao, W. & Coe, J. E. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 166, 1912–1920 (2001).
Carvalho, E. M. et al. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152, 5949–5956 (1994).
Karp, C. L. et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest 91, 1644–1648 (1993).
Article PubMed PubMed Central Google Scholar
Poudel, B. et al. Acute IL-4 governs pathogenic T cell responses during Leishmania major Infection. Immunohorizons 4, 546–560 (2020).
Article PubMed PubMed Central Google Scholar
Padigel, U. M., Alexander, J. & Farrell, J. P. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J. Immunol. 171, 3705–3710 (2003).
Alexander, J. et al. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur. J. Immunol. 32, 2923–2933 (2002).
Bryson, K. J. et al. BALB/c mice deficient in CD4 T cell IL-4Ralpha expression control Leishmania mexicana Load although female but not male mice develop a healer phenotype. PLoS Negl. Trop. Dis. 5, e930 (2011).
Article PubMed PubMed Central Google Scholar
Satoskar, A., Bluethmann, H. & Alexander, J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63, 4894–4899 (1995).
Article PubMed PubMed Central Google Scholar
Parkash, V., Kaye, P. M., Layton, A. M. & Lacey, C. J. Vaccines against leishmaniasis: using controlled human infection models to accelerate development. Expert Rev. Vaccin. 20, 1407–1418 (2021).
留言 (0)